Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator’s choice. As a first-in-class therapeutic option, this...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2023
|
| In: |
European journal of cancer
Year: 2023, Jahrgang: 191, Pages: 1-12 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.112986 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2023.112986 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923003386 
|
| Verfasserangaben: | Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Meier, Sebastian Ochsenreither, Jens Siveke, Axel Hauschild, Dirk Schadendorf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1872974767 | ||
| 003 | DE-627 | ||
| 005 | 20240331080358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231208s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.112986 |2 doi | |
| 035 | |a (DE-627)1872974767 | ||
| 035 | |a (DE-599)KXP1872974767 | ||
| 035 | |a (OCoLC)1425208404 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 245 | 1 | 0 | |a Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp |c Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Meier, Sebastian Ochsenreither, Jens Siveke, Axel Hauschild, Dirk Schadendorf |
| 264 | 1 | |c September 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 11. Juli 2023, Artikelversion: 16. August 2023 | ||
| 500 | |a Gesehen am 08.12.2023 | ||
| 520 | |a Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator’s choice. As a first-in-class therapeutic option, this Immune mobilising monoclonal T cell receptor Against Cancer (ImmTAC) is associated with a new adverse event (AE) profile. Based on clinical experience, a national expert group discussed recommendations for tebentafusp treatment, focusing on AE management. Further topics included prerequisites for initiating tebentafusp treatment, appropriate treatment setting, and patient selection criteria. To provide guidance for treating physicians, the resulting recommendations are summarised including a model standard operating procedure for AE management. Patients in good clinical condition and with a low tumour burden are good candidates for tebentafusp treatment, particularly if treated as early as possible after the diagnosis of metastatic disease. The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events. Postdose monitoring should thus focus on pyrexia and hypotension as the first symptoms of cytokine release. To minimise the risk of hypotension associated with CRS, patients should receive intravenous fluids before starting treatment. The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome. | ||
| 650 | 4 | |a Adverse event management | |
| 650 | 4 | |a Bispecific | |
| 650 | 4 | |a Cytokine release syndrome | |
| 650 | 4 | |a Expert opinion | |
| 650 | 4 | |a Immune mobilising monoclonal T cell receptor against cancer (ImmTAC) | |
| 650 | 4 | |a Skin toxicity | |
| 650 | 4 | |a Tebentafusp | |
| 650 | 4 | |a Treatment recommendation | |
| 650 | 4 | |a Uveal melanoma | |
| 700 | 1 | |a Berking, Carola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Forschner, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gebhardt, Christoffer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzerling, Lucie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meier, Friedegund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ochsenreither, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siveke, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauschild, Axel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 191(2023) vom: Sept., Artikel-ID 112986, Seite 1-12 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp |
| 773 | 1 | 8 | |g volume:191 |g year:2023 |g month:09 |g elocationid:112986 |g pages:1-12 |g extent:12 |a Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.112986 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923003386 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231208 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 10 |y j | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1872974767 |e 4429073031 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1872974767","physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"person":[{"family":"Hassel","role":"aut","given":"Jessica C.","display":"Hassel, Jessica C."},{"display":"Berking, Carola","family":"Berking","role":"aut","given":"Carola"},{"display":"Forschner, Andrea","given":"Andrea","role":"aut","family":"Forschner"},{"display":"Gebhardt, Christoffer","family":"Gebhardt","role":"aut","given":"Christoffer"},{"display":"Heinzerling, Lucie","role":"aut","given":"Lucie","family":"Heinzerling"},{"given":"Friedegund","role":"aut","family":"Meier","display":"Meier, Friedegund"},{"display":"Ochsenreither, Sebastian","family":"Ochsenreither","role":"aut","given":"Sebastian"},{"family":"Siveke","given":"Jens","role":"aut","display":"Siveke, Jens"},{"role":"aut","given":"Axel","family":"Hauschild","display":"Hauschild, Axel"},{"display":"Schadendorf, Dirk","given":"Dirk","role":"aut","family":"Schadendorf"}],"relHost":[{"pubHistory":["28.1992 -"],"titleAlt":[{"title":"EJC online"}],"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"part":{"pages":"1-12","year":"2023","volume":"191","text":"191(2023) vom: Sept., Artikel-ID 112986, Seite 1-12","extent":"12"},"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"recId":"266883400","disp":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspEuropean journal of cancer"}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"September 2023"}],"title":[{"title_sort":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp"}],"note":["Online verfügbar: 11. Juli 2023, Artikelversion: 16. August 2023","Gesehen am 08.12.2023"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Meier, Sebastian Ochsenreither, Jens Siveke, Axel Hauschild, Dirk Schadendorf"]},"id":{"doi":["10.1016/j.ejca.2023.112986"],"eki":["1872974767"]}} | ||
| SRT | |a HASSELJESSPRACTICALG2023 | ||